The DOI matches its Crossref record; 16 of the 17 references it cites were found in a registry or an index.
A decade of immune-checkpoint inhibitors in cancer therapy
Open accessAbstract
Immunotherapy using immune-checkpoint modulators revolutionizes the oncology field far beyond their remarkable clinical efficacy in some patients. It creates radical changes in the evaluation of treatment efficacy and toxicity with a more holistic vision of the patient with cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ICIs are cancer immunotherapies that boost anti-cancer immune responses by targeting immunologic receptors on the surface of T-lymphocytes (Table 1) [13].”
From Immune Checkpoint Inhibitors in Cancer Therapy (2022) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationOverall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910836 · Cited by 3,723
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C.-H., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,980
Wang, D. Y., Salem, J.-E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3923 · Cited by 2,674
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30074-8 · Cited by 2,472
Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709030 · Cited by 2,246
Adjuvant pembrolizumab versus placebo in resected stage III melanoma
Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802357 · Cited by 1,906
Self-citationSafety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Boutros, C., Tarhini, A. A., Routier, É., Lambotte, O., Ladurie, F. L. R., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,100
Self-citation
Cited by
Sorted by citations
Items 701–800 of 1,000
Yuan, W. M., Xiao, J., Zhang, J., Mao, B., Wang, P.-Z., & Wang, B.-L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1153353 · Cited by 12
Case Report: ICIs-induced Guillain–Barré syndrome recovered from mycophenolate mofetil
Ding, M.-G., Deng, C., Liu, X., Jiang, S., Gao, Y. J., Fan, D., Zhou, Y., He, J., & Liu, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1132692 · Cited by 13
Dong, T., Shah, J. R., Phung, A. T., Larson, C., Sanchez, A. B., Aisagbonhi, O. A., Blair, S. L., Oronsky, B. T., Trogler, W. C., Reid, T. R., et al. (2023) · Cancers · doi:10.3390/cancers15123157 · Cited by 12
Gao, W., Liu, Q., Zhou, Y., Yang, M., & Yu, Y. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338231206705 · Cited by 12
CheckMate 9LA: broadening treatment options for patients with non-small-cell lung cancer
Passaro, A., Attili, I., & de Marinis, F. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30701-4 · Cited by 12
Ghidini, M., Petrillo, A., Botticelli, A., Trapani, D., Parisi, A., Salvia, A. L., Sajjadi, E., Piciotti, R., Fusco, N., & Khakoo, S. S. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071412 · Cited by 12
Walters, A. A., Dhadwar, B., & Al‐Jamal, K. T. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103624 · Cited by 13
The Neonatal Fc Receptor Is Elevated in Monocyte-Derived Immune Cells in Pancreatic Cancer
Thomas, J. W., Torok, M. A., Agrawal, K., Pfau, T., Vu, T. T., Lyberger, J. M., Chang, H., Castillo, A. M. M., Chen, M., Remaily, B., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137066 · Cited by 12
Polyester nanomedicines targeting inflammatory signaling pathways for cancer therapy
Das, S. S., Singh, S. K., Verma, P. R. P., Gahtori, R., Sibuh, B. Z., Kesari, K. K., Jha, N. K., Dhanasekaran, S., Thakur, V. K., Wong, L. S., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113654 · Cited by 12
Heterogeneity and the tumor microenvironment in neuroendocrine prostate cancer
Brady, L., & Nelson, P. S. (2022) · Journal of Endocrinology · doi:10.1530/joe-22-0211 · Cited by 12
Majocchi, S., Lloveras, P., Nouveau, L., Legrand, M., Viandier, A., Malinge, P., Charreton, M., Raymond, C., Pace, E. A., Millard, B. L., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0298 · Cited by 12
Going viral: targeting glioblastoma using oncolytic viruses
Coates, K., Nibbs, R. J. B., & Fraser, A. R. (2024) · Immunotherapy Advances · doi:10.1093/immadv/ltaf024 · Cited by 13
Singleton, D. C., Mowday, A. M., Guise, C. P., Syddall, S. P., Bai, S. Y., Li, D., Ashoorzadeh, A., Smaill, J. B., Wilson, W. R., & Patterson, A. V. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00409-2 · Cited by 11
Edner, N. M., Ntavli, E., Petersone, L., Wang, C. J., Fabri, A., Kogimtzis, A., Ovcinnikovs, V., Ross, E. M., Heuts, F. W. H., Elfaki, Y., et al. (2023) · Immunotherapy Advances · doi:10.1093/immadv/ltad001 · Cited by 13
Wang, F. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03108-6 · Cited by 11
Herpels, M., Ishihara, J., & Sadanandam, A. (2023) · The Journal of Pathology · doi:10.1002/path.6171 · Cited by 11
Mathias, C., Kozak, V. N., Magno, J. M., Baal, S. C. S., dos Santos, V. H. A., Ribeiro, E. M. D. S. F., Gradia, D. F., Castro, M. A. A., & de Oliveira, J. C. (2023) · Cancers · doi:10.3390/cancers15194682 · Cited by 11
Design of cyclic peptides as novel inhibitors of ICOS/ICOSL interaction
Abdel‐Rahman, S. A., Santini, B. L., Calvo‐Barreiro, L., Zacharias, M., & Gabr, M. T. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.129599 · Cited by 11
GABA/baclofen stabilizes PD-L1 and enhances immunotherapy of breast cancer
Sun, X., Lin, M., Tian, Z., Ma, Y., & Lv, L. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28600 · Cited by 11
Magnetite nanoparticles: an emerging adjunctive tool for the improvement of cancer immunotherapy
Jungcharoen, P., Thivakorakot, K., Thientanukij, N., Kosachunhanun, N., Vichapattana, C., Panaampon, J., & Saengboonmee, C. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00220 · Cited by 13
Fu, Z., Liu, J., Zhang, C., Hu, H., Li, S., Zhang, Y., & You, R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1383212 · Cited by 11
Current mRNA-based vaccine strategies for glioma treatment
Mao, M., Yang, W., & Zhang, X. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104459 · Cited by 12
Endoscopic findings of immune checkpoint inhibitor-related gastrointestinal adverse events
Kim, M. K., & Hwang, S. W. (2024) · Clinical Endoscopy · doi:10.5946/ce.2024.003 · Cited by 11
Application and Expectations for Immune Checkpoint Blockade of LAG3 and TIGIT
Dumbrava, E. E. I., Frej, K. B. H., Sharon, E., & Tawbi, H. A.-H. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-080222-100847 · Cited by 11
Extracellular vesicles in cancer immunotherapy: Therapeutic, challenges and clinical progress
Manoochehri, H., La’ah, A. S., Babaeizad, A., Sheykhhasan, M., Rostamipoor, M., Abbaspoor, M., Nikravesh, F., Khosravi, S. M., Mahaki, H., Tanzadehpanah, H., et al. (2025) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2025.101065 · Cited by 11
Xu, C., Yang, J., Xiong, H., Cui, X., Zhang, Y., Gao, M., He, L., Fang, Q., Han, C., Liu, W., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-04862-z · Cited by 11
Alexander, C. A., & Yang, Y. Y. (2021) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2021.102492 · Cited by 12
Mitochondrial Proteins as Source of Cancer Neoantigens
Prota, G., Lechuga‐Vieco, A. V., & Libero, G. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052627 · Cited by 12
The prognostic impact of B7-H3 and B7-H4 in head and neck squamous cell carcinoma
Borgmann, M., Oetting, A., Meyer, F., Möckelmann, N., Droste, C., von Bargen, C. M., Möller‐Koop, C., Witt, M., Borgmann, K., Rothkamm, K., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04244-2 · Cited by 11
Glatiramer Acetate Complexed with CpG as Intratumoral Immunotherapy in Combination with Anti-PD-1
Huang, A., Groer, C. E., Lu, R., Forrest, M. L., Griffin, J. D., & Berkland, C. J. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00730 · Cited by 11
Lee, J., Hung, Y., Chou, K.-Y., Lee, C.-Y., Lin, S., Tsai, Y.-H., Lai, W.-Y., Shao, Y., Hsu, C., Hsu, C., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1008855 · Cited by 11
Immunotherapy for Pediatric Brain and Spine Tumors: Current State and Future Directions
Estévez-Ordoñez, D., Gary, S. E., Atchley, T. J., Maleknia, P. D., George, J. A., Laskay, N. M. B., Gross, E. G., Devulapalli, R. K., & Johnston, J. M. (2022) · Pediatric Neurosurgery · doi:10.1159/000528792 · Cited by 12
Rosado, M. M., & Pioli, C. (2023) · Cancers · doi:10.3390/cancers15041093 · Cited by 11
Li, L. X., Cappuzzo, F., Matos, I. G., Socinski, M. A., Hopkins, A. M., & Sorich, M. J. (2023) · The Oncologist · doi:10.1093/oncolo/oyad043 · Cited by 11
Liang, X., Lin, X., Lin, Z., Lin, W., Peng, Z., & Wei, S. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.106850 · Cited by 12
Wang, X., Dou, X., Ren, X., Rong, Z., Sun, L., Deng, Y., Chen, P., & Li, Z. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2021.763636 · Cited by 11
Cao, D., Song, Q., Li, J., Chard, L. S., Jiang, Y., Qin, B. Y., Wang, J., Guo, H., Cheng, Z., Wang, Z., et al. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.04.008 · Cited by 11
Lin, S.-H., Zhang, A., Li, L.-Z., Zhao, L.-C., Wu, L., & Fang, C. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01151-y · Cited by 11
Chan, J. S. K., Lee, S., Kong, D., Lakhani, I., Ng, K., Dee, E. C., Tang, P., Lee, Y. H. A., Satti, D. I., Wong, W. T., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.5616 · Cited by 10
Chemotherapy induces myeloid-driven spatial T-cell exhaustion in ovarian cancerPreprint
Launonen, I.-M. P., Erkan, E. P., Niemiec, I., Junquera, A., Hincapié-Otero, M. M., Afenteva, D., Liang, Z., Salko, M., Szabo, A., Pérez‐Villatoro, F., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.19.585657 · Cited by 11
Immune-based cancer therapies: mechanistic insights, clinical progress, and future directions
Devaraji, M., & Cheriyan, B. V. (2025) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-025-00319-6 · Cited by 16
Gastrointestinal cancer: molecular pathogenesis and targeted therapy
Jin, Y., He, X., & Wu, Y. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00361-9 · Cited by 13
AARS1-mediated lactylation of STAT1 drives immune evasion
Du, Y., He, M., Xu, Y., Tian, T., Zhou, Y., Zhang, Y., Fu, H., Li, J., Lv, L., & Xu, Y. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117094 · Cited by 10
Systemic therapy in pancreatic ductal adenocarcinomas (PDACs)—basis and current status
Ramaswamy, A., Srinivas, S., Chaudhari, V. A., BHARGAVA, P. G., BHANDARE, M. S., Shrikhande, S. V., & Ostwal, V. S. (2022) · ecancermedicalscience · doi:10.3332/ecancer.2022.1367 · Cited by 10
Thiopurine 6TG treatment increases tumor immunogenicity and response to immune checkpoint blockade
Nazerai, L., Willis, S. C., Yankilevich, P., Leo, L. D., Bosisio, F. M., Frías, A., Bertolotto, C., Nersting, J., Thastrup, M., Buus, S., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2158610 · Cited by 10
Current landscape and tailored management of immune-related adverse events
Liu, W., Luo, Z., Liu, Y., & Sun, B. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1078338 · Cited by 10
Choucair, K., Nebhan, C. A., Cortellini, A., Hentzen, S., Wang, Y., Liu, C., Giusti, R., Filetti, M., Ascierto, P. A., Vanella, V., et al. (2023) · Cancers · doi:10.3390/cancers15205052 · Cited by 11
Immune Checkpoints in Solid Organ Transplantation
Bello, A. D., & Treiner, E. (2023) · Biology · doi:10.3390/biology12101358 · Cited by 10
Green, C., Chacon, J. A., Godinich, B. M., Hock, R. A., Kiesewetter, M., Raynor, M., Marwaha, K., Maharaj, S. S., & Holland, N. A. (2023) · Cancers · doi:10.3390/cancers15245707 · Cited by 11
Omotesho, Q. A., Escamilla, A., Pérez-Ruiz, E., Frecha, C. A., Rueda‐Domínguez, A., & Barragán, I. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1348156 · Cited by 10
Basak, N. P., Jaganathan, K., Das, B., Muthusamy, O., Rajashekar, M. R., Malhotra, R., Samal, A., Nath, M., Ganesh, M. S., Shankar, A. P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45723-z · Cited by 10
Quarato, E. R., Salama, N., & Calvi, L. M. (2024) · Current Osteoporosis Reports · doi:10.1007/s11914-024-00874-2 · Cited by 11
Kawashima, A., Ishizuya, Y., Yamamoto, Y., Kato, T., Hatano, K., & Nonomura, N. (2024) · International Journal of Clinical Oncology · doi:10.1007/s10147-024-02526-y · Cited by 10
Pichon, S., Aigrain, P., Lacombe, C., Lemarchant, B., Ledoult, E., Koether, V., Leurs, A., Zebian, G., Launay, D., Gachet, B., et al. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12660-2 · Cited by 10
Zheng, M., Li, J., Guo, H., Zhang, J., Wang, L., Jiang, K.-F., Wu, H., He, Q., Ding, L., & Yang, B. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01411-8 · Cited by 11
Targeting Cancer: Microenvironment and Immunotherapy Innovations
Padzińska-Pruszyńska, I. B., Taciak, B., Kiraga, Ł., Smolarska, A., Górczak, M., Kucharzewska, P., Kubiak, M., Szeliga, J., Matejuk, A., & Król, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413569 · Cited by 11
McMorrow, R., de Bruijn, H. S., Farina, S., van Ardenne, R. J. L., Que, I., Mastroberardino, P. G., Robinson, D. J., Mezzanotte, L., & Löwik, C. W. G. M. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0733 · Cited by 10
Immune Checkpoint Inhibitor-Related Acute Kidney Injury: Management and Challenges
Youssef, N., & Abudayyeh, A. (2025) · American Journal of Nephrology · doi:10.1159/000543323 · Cited by 10
Shin, S. K., Mishima, Y., Lee, Y., Kwon, O. S., Kim, J. H., Kim, Y. S., & Kaneko, S. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16872 · Cited by 11
Shu, C., Li, J., Rui, J., Fan, D., Niu, Q., Bai, R., Cicka, D., Doyle, S. P., Wahafu, A., Zheng, X., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57297-5 · Cited by 11
Lakshmipathi, J., Santha, S., Li, M., Qian, Y., Roy, S. F., Luheshi, N., Politi, K. A., Bosenberg, M., Eyles, J. E., & Muthusamy, V. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04105-0 · Cited by 10
Li, Y., Yang, L., & Zd, L. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104883 · Cited by 11
Feng, C., Wang, Q., Xiao, S., Chen, B., Fan, R., Han, B. R., Zou, B., & Guo, G. F. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202511828 · Cited by 11
Liu, S., He, J., Song, R., Zhang, M., Huang, L.-H., Chen, J., Wang, M., Liu, F., & Zhou, F. (2021) · Nanophotonics · doi:10.1515/nanoph-2021-0196 · Cited by 10
Wu, W., Zhou, S., Liu, T., & Liang, D. (2022) · Bioengineered · doi:10.1080/21655979.2022.2074615 · Cited by 10
RetractedTew, A., Khoja, L., Pallan, L., & Steven, N. M. (2022) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552221103548 · Cited by 10
CIS and TGF ‐β regulatory pathways influence immunity to bacterial infection
McCulloch, T. R., Rossi, G. R., Schreuder, J., Belz, G. T., Wells, T. J., & Souza-Fonseca-Guimarães, F. (2022) · Immunology · doi:10.1111/imm.13516 · Cited by 10
Khandekar, D., Dahunsi, D. O., Esteve, I. V. M., Reid, S., Rathmell, J. C., Titze, J. M., & Tiriveedhi, V. (2022) · Biology · doi:10.3390/biology11060810 · Cited by 10
Onwuemene, O. A., Nnoruka, C. I., Patriquin, C. J., & Connelly‐Smith, L. S. (2022) · Transfusion · doi:10.1111/trf.17114 · Cited by 10
Corneal Transplant Rejections in Patients Receiving Immune Checkpoint Inhibitors
Moshirfar, M., Basharat, N. F., Seitz, T. S., Ply, B. K., Ronquillo, Y. C., & Hoopes, P. C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195647 · Cited by 10
Zhang, X., Wen, J., Zhang, G., Fan, W., Tan, J., Liu, H., & Li, J. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101600 · Cited by 10
Chemo-immunoablation of solid tumors: A new concept in tumor ablation
Meng, L., Wei, Y., & Xiao, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1057535 · Cited by 10
Long, L., Gao, J. J., & Zhang, R. (2023) · Viruses · doi:10.3390/v15051153 · Cited by 10
Uhlik, M. T., Pointing, D., Iyer, S., Ausec, L., Štajdohar, M. R., Cvitkovič, R., Žganec, M., Culm, K., Santos, V. C., Pytowski, B., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1158345 · Cited by 10
Lee, S., Choi, Y.-H., Kang, S. M., Lee, M.-G., Debin, A., Pérouzel, É., Hong, S., & Kim, D.-H. (2023) · Cancers · doi:10.3390/cancers15245752 · Cited by 10
IL-27 in combination with anti-PD-1 can be anti-cancer or pro-cancer
Liao, K., Bai, X., & Friedman, A. (2023) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2023.111704 · Cited by 10
Endocrine toxicity of immune checkpoint inhibitors: a network meta-analysis of the current evidence
Ouyang, P., Yang, W., Sun, J., Chen, P., He, Q., Yan, J., Wang, W., Wang, Y., Li, H., & Luo, Q. (2024) · Acta Materia Medica · doi:10.15212/amm-2023-0037 · Cited by 10
Fujiwara, Y., Kato, S., Nishizaki, D., Miyashita, H., Lee, S., Nesline, M., Conroy, J. M., DePietro, P., Pabla, S., Lippman, S. M., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109632 · Cited by 11
Tumor neoantigens and tumor immunotherapies
Jiani, W., Qin, T., & Ma, J. (2024) · Aging Medicine · doi:10.1002/agm2.12295 · Cited by 12
Making HSP90 Inhibitors Great Again? Unite for Better Cancer Immunotherapy
Graner, M. W. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.02.002 · Cited by 10
Lu, B., Liu, D., Gui, B., Gou, J., Dong, H., Hu, Q., Feng, J., Mao, Y., Shen, X., Wang, S., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00828 · Cited by 10
Understanding resistance to immune checkpoint inhibitors in advanced breast cancer
Tarantino, P., Barroso‐Sousa, R., Garrido-Castro, A. C., McAllister, S. S., Guerriero, J. L., Mittendorf, E. A., Curigliano, G., & Tolaney, S. M. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2020650 · Cited by 10
Charneau, J., Suzuki, T., Shimomura, M., Fujinami, N., Mishima, Y., Hiranuka, K., Watanabe, N., Yamada, T., Nakamura, N., & Nakatsura, T. (2022) · Cancer Science · doi:10.1111/cas.15291 · Cited by 9
The Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma
Ghasemi, D. R., Fleischhack, G., Milde, T., & Pajtler, K. W. (2022) · Cancers · doi:10.3390/cancers14030679 · Cited by 11
Fialová, J. L., Hönigová, K., Raudenská, M., Mikšátková, L., Zobalová, R., Navrátil, J., Šmigová, J., Moturu, T. R., Vičar, T., Balvan, J., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113582 · Cited by 10
Shek, D., Gloss, B., Lai, J., Ma, L., Zhang, H. E., Carlino, M. S., Mahajan, H., Nagrial, A. M., Gao, B., Read, S. A., et al. (2023) · Methods and Protocols · doi:10.3390/mps6020035 · Cited by 11
Ando, Y., Nishiyama, H., Shimodaira, H., Takano, N., Sakaida, E., Matsumoto, K., Nakanishi, K., Sakai, H., Tsukamoto, S., Komine, K., et al. (2023) · International Journal of Clinical Oncology · doi:10.1007/s10147-023-02382-2 · Cited by 10
Durojaye, O. A., Ejaz, U., Uzoeto, H. O., Fadahunsi, A. A., Opabunmi, A. O., Ekpo, D. E., Sedzro, D. M., & Idris, M. O. (2023) · Amino Acids · doi:10.1007/s00726-023-03304-2 · Cited by 11
Minkove, S. J., Sun, J., Li, Y., Cui, X., Cooper, D., Eichacker, P. Q., & Torabi‐Parizi, P. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2352 · Cited by 10
Launonen, I.-M. P., Vähärautio, A., & Färkkilä, A. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041314 · Cited by 10
Huang, D. D.-R., Liao, B.-C., Hsu, W., Yang, C., Lin, Y., Wu, S., Tsai, T.-H., Chen, K.-Y., Ho, C., Liao, W., et al. (2023) · Oncology · doi:10.1159/000534350 · Cited by 10
Prognosis and immunotherapy response prediction based on M2 macrophage-related genes in colon cancer
Xu, X., Zhang, X., Kou, R., Liu, Y., Chen, S., Li, Z., Jian, Z., & Wang, Z. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05573-6 · Cited by 9
Toward a Wireless Image Sensor for Real-Time Fluorescence Microscopy in Cancer Therapy
Rabbani, R., Najafiaghdam, H., Roschelle, M., Papageorgiou, E. P., Zhao, B. R., Ghanbari, M. M., Muller, R., Stojanovic, V. M., & Anwar, M. (2024) · IEEE Transactions on Biomedical Circuits and Systems · doi:10.1109/tbcas.2024.3374886 · Cited by 9
Logotheti, S., Pavlopoulou, A., Rudsari, H. K., Galow, A.-M., Kafalı, Y., Kyrodimos, E., Giotakis, A. Ι., Marquardt, S., Velalopoulou, A. P., Verginadis, I. I., et al. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108670 · Cited by 10
Wang, W., Mei, Z., Chen, Y., Jiang, J., Qu, Y., Keyoumu, S., Zhou, N., Bulibu, G., Tang, Y. C., Zhai, X., et al. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000002007 · Cited by 9
CRISPR/Cas-Mediated Knockdown of PD-L1 and KRAS in Lung Cancer Cells
Abounar, S. A., El-Nikhely, N. A., Turkowski, K., Savai, R., & Saeed, H. M. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25169086 · Cited by 9
Xiao, B., Shi, X., Xu, X., Liu, J., Pan, Y., Xu, H., Sun, W., Slater, N. K. H., Patra, H. K., Gao, J.-Q., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.08.043 · Cited by 9
Barbir, E., Abdulmoneim, S., Dudek, A. Z., & Kukla, A. (2024) · Transplant International · doi:10.3389/ti.2024.13322 · Cited by 9
Antibiotic-mediated selection of randomly mutagenized and cytokine-expressing oncolytic viruses
Rezaei, R., Boulton, S., Ahmadi, M., Petryk, J., Silva, M. D., Zamani, N. K., Singaravelu, R., St-Laurent, G., Daniel, L., Sadeghipour, A., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01259-7 · Cited by 9
Updates in Diagnosis and Treatment of Immune Checkpoint Inhibitor Myocarditis
Hachem, A. M., Desai, A., Beinart, N. I., Ostos-Mendoza, K. C., Rodriguez, A. S. L., Derby, R. D. D. L., Ebrahimi, S., & Palaskas, N. L. (2025) · Current Cardiology Reports · doi:10.1007/s11886-025-02232-9 · Cited by 9
Metadata
- Authors
- Robert, C.
- Affiliations
- Institut Gustave Roussy (FR)
- Corresponding author
- Robert, Caroline
- ORCID
- Robert, Caroline
- Venue
- Nature Communications
- Published
- 2020-07-30
- Volume
- 11
- Issue
- 1
- Pages
- 3801-3801
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC7393098
- OpenAlex
- W3045946240
- Cited by
- 1,608
- References
- 17
- Citations by year
- 2026: 154 · 2025: 250 · 2024: 312 · 2023: 339 · 2022: 315 · 2021: 227 · 2020: 9
- FWCI
- 80.61
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- immune checkpoint inhibitors, cancer immunotherapy, treatment efficacy assessment, immunotherapy toxicity, patient-centered care
- MeSH terms
- Antineoplastic Agents, Immunological, Ipilimumab, Nivolumab, Antibodies, Monoclonal, Humans, Immunotherapy, Neoplasms, B7-H1 Antigen, CTLA-4 Antigen, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
